Amova Asset Management Americas Inc. Has $24.48 Million Stock Position in Nurix Therapeutics, Inc. $NRIX

Amova Asset Management Americas Inc. lowered its stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 17.1% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 1,290,554 shares of the company’s stock after selling 266,925 shares during the period. Amova Asset Management Americas Inc.’s holdings in Nurix Therapeutics were worth $24,482,000 at the end of the most recent reporting period.

A number of other hedge funds also recently modified their holdings of the business. Vanguard Group Inc. lifted its holdings in shares of Nurix Therapeutics by 32.5% during the fourth quarter. Vanguard Group Inc. now owns 5,949,512 shares of the company’s stock worth $112,862,000 after purchasing an additional 1,460,736 shares during the period. Vestal Point Capital LP lifted its holdings in shares of Nurix Therapeutics by 73.8% during the third quarter. Vestal Point Capital LP now owns 3,475,000 shares of the company’s stock worth $32,109,000 after purchasing an additional 1,475,000 shares during the period. Pictet Asset Management Holding SA lifted its holdings in shares of Nurix Therapeutics by 75.1% during the fourth quarter. Pictet Asset Management Holding SA now owns 3,467,600 shares of the company’s stock worth $65,780,000 after purchasing an additional 1,487,060 shares during the period. Deutsche Bank AG lifted its holdings in shares of Nurix Therapeutics by 72.8% during the fourth quarter. Deutsche Bank AG now owns 2,486,792 shares of the company’s stock worth $47,174,000 after purchasing an additional 1,047,933 shares during the period. Finally, Geode Capital Management LLC lifted its holdings in shares of Nurix Therapeutics by 26.7% during the fourth quarter. Geode Capital Management LLC now owns 2,384,998 shares of the company’s stock worth $45,250,000 after purchasing an additional 502,316 shares during the period.

Insider Activity

In other news, CFO Houte Hans Van sold 14,055 shares of the business’s stock in a transaction dated Tuesday, May 5th. The shares were sold at an average price of $16.60, for a total transaction of $233,313.00. Following the completion of the sale, the chief financial officer directly owned 37,592 shares of the company’s stock, valued at $624,027.20. The trade was a 27.21% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Gwenn Hansen sold 3,214 shares of the business’s stock in a transaction dated Thursday, April 30th. The stock was sold at an average price of $16.65, for a total transaction of $53,513.10. Following the sale, the insider directly owned 120,399 shares of the company’s stock, valued at approximately $2,004,643.35. The trade was a 2.60% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders have sold 19,657 shares of company stock valued at $326,586. 6.70% of the stock is currently owned by insiders.

Nurix Therapeutics Stock Performance

NRIX opened at $15.64 on Wednesday. Nurix Therapeutics, Inc. has a 1-year low of $8.19 and a 1-year high of $22.50. The company has a market cap of $1.62 billion, a P/E ratio of -4.95 and a beta of 1.86. The company has a fifty day moving average price of $16.35 and a two-hundred day moving average price of $16.91.

Nurix Therapeutics (NASDAQ:NRIX) last posted its earnings results on Wednesday, April 8th. The company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.03). The business had revenue of $6.25 million for the quarter, compared to the consensus estimate of $14.25 million. Nurix Therapeutics had a negative return on equity of 64.21% and a negative net margin of 411.37%. On average, research analysts forecast that Nurix Therapeutics, Inc. will post -2.94 EPS for the current fiscal year.

Key Headlines Impacting Nurix Therapeutics

Here are the key news stories impacting Nurix Therapeutics this week:

• Positive Sentiment: Roche’s collaboration with Nurix on bexobrutideg includes $700 million upfront and up to $2.3 billion in total payments, signaling strong external validation of Nurix’s pipeline and creating a meaningful funding source. Reuters article
• Positive Sentiment: The deal expands bexobrutideg’s development into blood cancers, immunology, and neurology, increasing the drug’s addressable market and upside potential for Nurix. Company release
• Positive Sentiment: Multiple analysts raised price targets following the announcement, with BTIG, Jefferies, and Needham all reiterating buy ratings and higher targets, reinforcing bullish sentiment around NRIX. Analyst update
• Neutral Sentiment: Recent commentary noted that short interest was reported at 0 shares, which does not provide a meaningful signal for the stock’s near-term direction.
• Negative Sentiment: Wells Fargo downgraded Nurix Therapeutics to “hold” from “overweight” and trimmed its price target, creating a small offset to the otherwise very upbeat news flow. Analyst downgrade

Analysts Set New Price Targets

A number of brokerages have recently commented on NRIX. HC Wainwright reiterated a “buy” rating and set a $32.00 price target on shares of Nurix Therapeutics in a report on Monday, April 27th. BTIG Research lifted their price target on shares of Nurix Therapeutics from $30.00 to $32.00 and gave the stock a “buy” rating in a report on Tuesday. Needham & Company LLC lifted their price target on shares of Nurix Therapeutics from $26.00 to $34.00 and gave the stock a “buy” rating in a report on Monday. Truist Financial lifted their price target on shares of Nurix Therapeutics from $30.00 to $32.00 and gave the stock a “buy” rating in a report on Monday. Finally, Wells Fargo & Company lowered shares of Nurix Therapeutics from an “overweight” rating to a “hold” rating and dropped their target price for the company from $28.00 to $25.00 in a report on Monday. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $32.14.

About Nurix Therapeutics

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.